Jing Zeng

Dr. Jing Zeng

Southwest Medical University, Luzhou, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Cancer Letters
Verified
Journal Article
Closed access
GQGuihui Qin
Guihui Qin
MLMin Luo
Min Luo
JCJunze Chen
Junze Chen
YDYiwu Dang
Yiwu Dang
GCGang Chen
Gang Chen
JYJie yang
Jie yang

1 October 2018 in Journal of Chromatography A
Verified
Journal Article
Closed access
DZDi Zhou
Di Zhou
JZJing Zeng
Jing Zeng
QFQifeng Fu
Qifeng Fu
DGDie Gao
Die Gao
KZKailian Zhang
Kailian Zhang
LWLujun Wang
Lujun Wang

20 September 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PZPing Zhou
Ping Zhou
JLJingyan Li
Jingyan Li
QCQi Chen
Qi Chen
LWLong Wang
Long Wang
JYJing Yang
Jing Yang
WJWu Jianming
Wu Jianming
Genus Sanguisorba (family: Rosaceae) comprises nearly 148 species, distributed widely across the temperate and subtropical regions of the Northern Hemisphere. Sanguisorba officinalis L. (S. officinalis) has been used as a hemostatic and scald treating medicine in China for a long time. Numerous studies have demonstrated that plant extracts or monomers from S. officinalis exhibit several pharmacological effects, such as anti-cancer, anti-virus, anti-inflammation, anti-bacteria, neuroprotective and hepatoprotective effects. The other species of genus Sanguisorba are also being studied by researchers worldwide. Sanguisorba minor Scop. (S. minor), as an edible wild plant, is a common ingredient of the Mediterranean diet, and its young shoots and leaves are often mixed with traditional vegetables and consumed as salad. Reports on genus Sanguisorba available in the current literature were collected from Google Scholar, Web of Science, Springer, and PubMed. The Plant List (http://www.theplantlist.org./tpl1.1/search?q=Sanguisorba), International Plant Name Index (https://www.ipni.org/?q=Sanguisorba) and Kew Botanical Garden (http://powo.science.kew.org/) were used for obtaining the scientific names and information on the subspecies and cultivars. In recent years, several in vivo and in vitro experiments have been conducted to reveal the active components and effective monomers of S. officinalis and S. minor. To date, more than 270 compounds have been isolated and identified so far from the species belonging to genus Sanguisorba. Numerous reports on the chemical constituents, pharmacologic effects, and toxicity of genus Sanguisorba are available in the literature. This review provides a comprehensive understanding of the current traditional applications of plants, which are supported by a large number of scientific experiments. Owing to these promising properties, this species is used in the treatment of various diseases, including influenza virus infection, inflammation, Alzheimer’s disease, type 2 diabetes and leukopenia caused by bone marrow suppression. Moreover, the rich contents and biological effects of S. officinalis and S. minor facilitate these applications in dietary supplements and cosmetics. Therefore, the purpose of this review is to summarize the recent advances in the traditional uses, chemical constituents, pharmacological effects and clinical applications of genus Sanguisorba. The present comprehensive review may provide new insights for the future research on genus Sanguisorba.

1 January 2012 in Journal of Chromatography A
Verified
Journal Article
Closed access
JZJing Zeng
Jing Zeng
XZXiuli Zhang
Xiuli Zhang
ZGZhimou Guo
Zhimou Guo
JFJiatao Feng
Jiatao Feng
JZJianguo Zeng
Jianguo Zeng
XLXinmiao Liang
Xinmiao Liang

27 November 2021 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
JLJing Lin
Jing Lin
JZJing Zeng
Jing Zeng
SLSha Liu
Sha Liu
XSXin Shen
Xin Shen
NJNan Jiang
Nan Jiang
WJWu Jianming
Wu Jianming
Background: Thrombocytopenia is one of the most common hematological disease that can be life-threatening caused by bleeding complications. However, the treatment options for thrombocytopenia remain limited. Methods: In this study, giemsa staining, phalloidin staining, immunofluorescence and flow cytometry were used to identify the effects of 3,3ʹ-di-O-methylellagic acid 4ʹ-glucoside (DMAG), a natural ellagic acid derived from Sanguisorba officinalis L. (SOL) on megakaryocyte differentiation in HEL cells. Then, thrombocytopenia mice model was constructed by X-ray irradiation to evaluate the therapeutic action of DMAG on thrombocytopenia. Furthermore, the effects of DMAG on platelet function were evaluated by tail bleeding time, platelet aggregation and platelet adhesion assays. Next, network pharmacology approaches were carried out to identify the targets of DMAG. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to elucidate the underling mechanism of DMAG against thrombocytopenia. Finally, molecular docking simulation, molecular dynamics simulation and western blot analysis were used to explore the relationship between DAMG with its targets. Results: DMAG significantly promoted megakaryocyte differentiation of HEL cells. DMAG administration accelerated platelet recovery and megakaryopoiesis, shortened tail bleeding time, strengthened platelet aggregation and adhesion in thrombocytopenia mice. Network pharmacology revealed that ITGA2B, ITGB3, VWF, PLEK, TLR2, BCL2, BCL2L1 and TNF were the core targets of DMAG. GO and KEGG pathway enrichment analyses suggested that the core targets of DMAG were enriched in PI3K–Akt signaling pathway, hematopoietic cell lineage, ECM-receptor interaction and platelet activation. Molecular docking simulation and molecular dynamics simulation further indicated that ITGA2B, ITGB3, PLEK and TLR2 displayed strong binding ability with DMAG. Finally, western blot analysis evidenced that DMAG up-regulated the expression of ITGA2B, ITGB3, VWF, p-Akt and PLEK. Conclusion: DMAG plays a critical role in promoting megakaryocytes differentiation and platelets production and might be a promising medicine for the treatment of thrombocytopenia. Graphical

1 October 2012 in Toxicology Letters
Verified
Journal Article
Closed access
DCDong-Ni Chen
Dong-Ni Chen
JZJing Zeng
Jing Zeng
FWFeng Wang
Feng Wang
WZWei Zheng
Wei Zheng
WTWei-Wei Tu
Wei-Wei Tu
JXJin Xu
Jin Xu